ClinicalTrials.gg
Active, not recruitingNCT07710716CATTALYSTUpdated Oct 13, 2026

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

An observational study in Breast Cancer, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know · 2 judgments

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Breast Neoplasms by Novartis — 17 open to participants now, 31 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
7th of 39
3,000 · median 595
Started
2026
with 10 others
Observational
39 of 200
8 open now
Primary completion
2028-06
later than 12 of 30 live
Registered
197th of 200
by date

Among the 200 studies in Breast Neoplasms by Novartis, this one is the 7th largest by planned enrollment of the 39 observational ones that give a count, is one of 11 that started in 2026, is one of 39 observational ones, reaches primary completion later than 12 of the 30 other live ones, and was the 197th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 200 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

The aim of this study is to assess the clinical adoption, treatment patterns, and safety of adjuvant ribociclib use in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) patients. This is a multi-country study using secondary real-world data sources.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Early Breast Cancer
  • HR+/HER2-
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with HR+/HER2- eBC who have undergone surgical resection of the primary breast tumor and initiated adjuvant ET.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of diagnosis of eBC during the identification period.
  2. Aged ≥18 years at index diagnosis date. The index diagnosis date is the date of first diagnosis of eBC.
  3. Anatomic stage I-III breast cancer (BC) per American Joint Committee on Cancer (AJCC), 8th Edition at index diagnosis date.
  4. Evidence of HR+ during the study period:

    1. have tested positive for estrogen receptor (ER+), or
    2. have tested positive for progesterone receptor (PR+), or
    3. have tested positive for both.
  5. Tested negative for (HER2-) during the study period.
  6. Evidence of surgical resection of the primary breast tumor at any time.
  7. Received endocrine therapy (ET) in the setting after index diagnosis date.

Exclusion criteria

Exclusion criteria:

  1. Evidence of another secondary at any time prior to index diagnosis date.
  2. Evidence of other primary cancer (except for skin cancer) at any time prior to index diagnosis date.
  3. Patients who participate in an interventional clinical trial at any time prior to or during the study period.
  4. Patients with severely incomplete or inconsistent data, precluding validity of results.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A: Contemporaneous Ribociclib-eligible Patients

    Adult HR+/HER2- eBC patients who have undergone surgical resection of the primary breast tumor and initiated adjuvant ET and meet additional staging criteria including either Stage III, or Stage IIB, or Stage IIA with N1, Stage IIA with N0 and Grade 3, or Stage IIA with N0 and Grade 2 and Ki-67 ≥20% or high genomic risk.

  • Cohort B: Ribociclib-treated Patients

    Adult HR+/HER2- eBC patients who have undergone surgical resection of the primary breast tumor and initiated adjuvant ribociclib in addition to ET.

  • Subcohort B1: Ribociclib-treated Subcohort for Landmark Safety Analysis

    Patients in Cohort B who have at least six months of potential follow-up time after ribociclib initiation at the time of the analysis.

This study also gives RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Cohort B and Subcohort B1: Proportion of Patients by Baseline Demographics and Clinical Characteristics

    Baseline characteristics (subject to data availability) include: * Age group * Sex * Race/Ethnicity * Geographic region * Insurance type * Menopausal status * Body mass index (BMI) category * Alcohol use * Year of initial BC diagnosis * Tumor stage and grade * Clinical pathological node and tumor stage * Multiple breast primary diagnoses (yes/no) * Eastern Cooperative Oncology Group (ECOG) performance status * Estrogen and progesterone receptor status * HER2 immunohistochemistry (IHC) test results (0, 1+, 2+, 3+) * HER2 Fluorescence In Situ Hybridization (FISH) test (positive, negative) * Ki-67 category (positive, negative) * Genomic risk score * Hepatic dysfunction (yes/no) * Renal dysfunction (yes/no) * Cardiovascular disease (yes/no) * Gastrointestinal (GI) dysfunction (yes/no)

    Time frame: Baseline

  2. Cohort B and Subcohort B1: Proportion of Patients by Demographics and Clinical Characteristics at Index Treatment Date

    The index treatment date is the date of adjuvant ribociclib treatment initiation. Demographics and clinical characteristics (subject to data availability) include: * Age group * Insurance type * Menopausal status * BMI category * ECOG performance status

    Time frame: Baseline

  3. Cohort B and Subcohort B1: Charlson Comorbidity Index (CCI)

    CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).

    Time frame: Baseline

  4. Cohort B and Subcohort B1: AST Levels at Index Diagnosis Date and Index Treatment Date

    Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.

    Time frame: Baseline

  5. Cohort B and Subcohort B1: ALT Levels at Index Diagnosis Date and Index Treatment Date

    Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.

    Time frame: Baseline

  6. Cohort B and Subcohort B1: Total Bilirubin Level at Index Diagnosis Date and Index Treatment Date

    Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.

    Time frame: Baseline

  7. Cohort B and Subcohort B1: QTc Interval at Index Diagnosis Date and Index Treatment Date

    Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.

    Time frame: Baseline

  8. Cohort B and Subcohort B1: Neutrophil Count at Index Diagnosis Date and Index Treatment Date

    Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.

    Time frame: Baseline

  9. Cohort B and Subcohort B1: Duration Between Initial Diagnosis and Ribociclib Initiation

    Time frame: Up to 40 months

  10. Cohort B and Subcohort B1: Duration Between Initial Diagnosis and Surgery

    Time frame: Up to 40 months

  11. Cohort B and Subcohort B1: Duration Between Surgery and Ribociclib Initiation

    Time frame: Up to 40 months

  12. Cohort B and Subcohort B1: Proportion of Patients by Type of Surgery Prior to Ribociclib Initiation

    Time frame: Up to 40 months

  13. Cohort B and Subcohort B1: Proportion of Patients by Type of BC Treatment Prior to Ribociclib Initiation

    Time frame: Up to 40 months

  14. Cohort B and Subcohort B1: Duration of Neoadjuvant and Adjuvant Therapy by Type, Prior to Ribociclib Initiation

    Time frame: Up to 40 months

  15. Cohort B and Subcohort B1: Proportion of Patients by Year of ET Initiation, Prior to Ribociclib Initiation

    Time frame: Up to 40 months

  16. Cohort B and Subcohort B1: Duration of ET by Type, Prior to Ribociclib Initiation

    Time frame: Up to 40 months

  17. Cohort B and Subcohort B1: Duration of Other Cyclin-dependent Kinase 4/6 Inhibitor (CDK4/6i) Treatment by Type, Prior to Ribociclib Initiation

    Time frame: Up to 40 months

Secondary outcomes

  1. Cohort A: Proportion of Patients by Baseline Demographics and Clinical Characteristics

    Baseline characteristics (subject to data availability) include: * Age group * Sex * Race/ethnicity * Geographic region * Insurance type * Menopausal status * BMI category * Alcohol use * Year of initial BC diagnosis * Tumor stage and grade * Clinical pathological node and tumor stage * Multiple breast primary diagnoses (yes/no) * ECOG performance status * Estrogen and progesterone receptor status * HER2 IHC test results (0, 1+, 2+, 3+) * HER2 FISH test (positive, negative) * Ki-67 category (positive, negative) * Genomic risk score * Hepatic dysfunction (yes/no) * Renal dysfunction (yes/no) * Cardiovascular disease (yes/no) * GI dysfunction (yes/no)

    Time frame: Baseline

  2. Cohort A: CCI

    CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).

    Time frame: Baseline

  3. Cohort A: Duration Between Initial Diagnosis and Surgery

    Time frame: Up to 58 months

  4. Cohort A: Proportion of Patients by Type of Surgery

    Time frame: Up to 58 months

  5. Cohort A: Proportion of Patients by Type of BC Treatment Received

    Time frame: Up to 58 months

  6. Cohort A: Duration of Neoadjuvant and Adjuvant Therapy by Type

    Time frame: Up to 58 months

  7. Cohort A: Proportion of Patients by Year of ET Initiation

    Time frame: Up to 58 months

  8. Cohort A: Duration of ET by Type

    Time frame: Up to 58 months

  9. Cohort A: Duration of Other CDK4/6i Treatment by Type

    Time frame: Up to 58 months

  10. Cohort A: Proportion of Patients by Type of Concomitant Medication Received

    Time frame: Up to 58 months

  11. Cohort B and Subcohort B1: Proportion of Patients Who Switch to an Alternative CDK4/6i

    Time frame: Up to 40 months

  12. Cohort B and Subcohort B1: Proportion of Patients Who Receive Concomitant Systemic and Local Oncology Therapies

    Time frame: Up to 40 months

  13. Cohort B and Subcohort B1: Proportion of Patients Who Receive Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation

    Time frame: Up to 40 months

  14. Cohort B and Subcohort B1: Duration of Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation, by Type of Therapy

    Time frame: Up to 40 months

  15. Cohort B and Subcohort B1: Time Between Discontinuation of Ribociclib and Start of Subsequent Systemic and Local Oncology Therapies, by Type of Therapy

    Time frame: Up to 40 months

  16. Cohort B and Subcohort B1: Initial Dose of Ribociclib

    Time frame: Baseline

  17. Cohort B and Subcohort B1: Proportion of Patients Who Undergo Ribociclib Dose Reduction

    Time frame: Up to 40 months

  18. Cohort B and Subcohort B1: Time to First Ribociclib Dose Reduction

    Time frame: Up to 40 months

  19. Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Reduction

    Time frame: Up to 40 months

  20. Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Dose Reduction

    Time frame: Up to 40 months

  21. Cohort B and Subcohort B1: Proportion of Patients Who Experience Ribociclib Dose Interruption

    Time frame: Up to 40 months

  22. Cohort B and Subcohort B1: Time to First Ribociclib Dose Interruption

    Time frame: Up to 40 months

  23. Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Interruption

    Time frame: Up to 40 months

  24. Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Dose Interruption

    Time frame: Up to 40 months

  25. Cohort B and Subcohort B1: Proportion of Patients Who Discontinue Ribociclib Treatment

    Time frame: Up to 40 months

  26. Cohort B and Subcohort B1: Time-to-Discontinuation (TTD) of Ribociclib Treatment

    Time frame: Up to 40 months

  27. Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Discontinuation

    Time frame: Up to 40 months

  28. Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Discontinuation

    Time frame: Up to 40 months

  29. Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Discontinuation

    Time frame: Up to 40 months

  30. Cohort B and Subcohort B1: Persistence of Ribociclib Treatment

    Persistence of ribociclib treatment, defined as the proportion of days covered (PDC) from the first prescription of ribociclib to data cut-off, discontinuation, or end of treatment.

    Time frame: Up to 40 months

  31. Cohort B and Subcohort B1: Number of Clinical Visits and/or Laboratory Assessments for Ribociclib Monitoring

    Time frame: Up to 40 months

  32. Cohort B and Subcohort B1: Cumulative Exposure to Ribociclib

    Cumulative exposure to ribociclib, measured as the dose of ribociclib multiplied by days received for each prescription during the treatment duration (original dose to discontinuation).

    Time frame: Up to 40 months

  33. Subcohort B1: Incidence of Adverse Events (AEs) of Interest

    AEs of interest include liver enzyme elevation, QT interval prolongation, neutropenia, fatigue, leukopenia, thrombocytopenia, anemia, infections, and interstitial lung disease/pneumonitis.

    Time frame: Up to 6 months

  34. Subcohort B1: Proportion of Patients Requiring Changes to the Ribociclib Regimen Following AE Occurrence

    Changes to ribociclib regimen include dose reduction, dose interruption, treatment discontinuation, switching to another CDK4/6i, and initiating supportive therapies.

    Time frame: Up to 6 months

  35. Subcohort B1: Proportion of Patients by the Sequalae of AEs

    Sequalae of AEs reported as follows: amelioration (improvement) of AE, progression of AE, resolution of AE, and recurrence of AE.

    Time frame: Up to 6 months

  36. Cohort B and Subcohort B1: Proportion of Patients Undergoing Drug-drug Interaction (DDI) Assessment Upon Ribociclib Initiation

    Time frame: Up to 40 months

  37. Cohort B and Subcohort B1: Proportion of Patients With Actual DDIs

    Actual DDIs will be defined based on clinical manifestation, assessed based on available data in each data set.

    Time frame: Up to 40 months

  38. Cohort B and Subcohort B1: Number of DDIs per Patient

    Time frame: Up to 40 months

  39. Cohort A: Proportion of Patients With Potential DDIs

    Potential DDIs will be defined as concomitant administration of ribociclib with another drug that can potentially alter the efficacy and safety of the interacting treatments.

    Time frame: Up to 58 months

  40. Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs

    Potential DDIs will be defined as concomitant administration of ribociclib with another drug that can potentially alter the efficacy and safety of the interacting treatments.

    Time frame: Up to 40 months

  41. Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs Who Experience AEs

    Time frame: Up to 40 months

  42. Cohort B and Subcohort B1: Proportion of Patients by Clinical Monitoring Practices Before and After DDI Occurrence

    Time frame: Up to 40 months

  43. Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by Demographics and Clinical Characteristics

    Demographics and clinical characteristics include * Age group * Sex * Race/ethnicity * Geographic region * Insurance type * Menopausal status * BMI category * Alcohol use * Year of initial BC diagnosis * Tumor stage and grade * Clinical pathological node and tumor stage * Multiple breast primary diagnoses (yes/no) * ECOG performance status * Estrogen and progesterone receptor status * HER2 IHC test results (0, 1+, 2+, 3+) * HER2 FISH test (positive, negative) * Ki-67 category (positive, negative) * Genomic risk score * Hepatic dysfunction (yes/no) * Renal dysfunction (yes/no) * Cardiovascular disease (yes/no) * GI dysfunction (yes/no)

    Time frame: Up to 40 months

  44. Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by BC Treatment Prior to Ribociclib

    Time frame: Up to 40 months

  45. Cohort B and Subcohort B1: Frequency of Ribociclib Treatment Modifications Related to DDIs

    Treatment modifications include dose adjustments, interruptions, reductions, discontinuations, and switches to other therapies.

    Time frame: Up to 40 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Jun 2028 and completion Sep 2026 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Jun 30, 2028was Sep 2026
CompletionEst.
Jun 30, 2028was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Jun 30, 2028
Oct 13, 2026
Study completion
Sep 30, 2026→Jun 30, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Sep 30, 2026→Jun 30, 2028
    Study completion Sep 30, 2026→Jun 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07710716
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Apr 9, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion